METASTATIC SQUAMOUS CELL CARCINOMA
Clinical trials for METASTATIC SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New dosing strategy could improve chemo for head and neck cancer patients
Disease control Recruiting nowThis study compares two different schedules of the chemotherapy drug 5-FU in people with advanced head and neck cancer that has not responded to platinum and immunotherapy. The goal is to see which schedule works better at shrinking tumors and has fewer side effects. About 46 par…
Matched conditions: METASTATIC SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated May 26, 2026 07:53 UTC
-
New Triple-Drug attack on head and neck cancer shows promise in early trial
Disease control Recruiting nowThis early-phase study tests a new three-drug combination for people with head and neck cancer that has come back or spread. The goal is to find the safest dose and see if the treatment can shrink tumors or slow the disease. About 36 adults with this type of cancer will take part…
Matched conditions: METASTATIC SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: University of Chicago • Aim: Disease control
Last updated May 22, 2026 14:05 UTC
-
New weekly drug combo offers hope for head and neck cancer patients unable to take standard chemo
Disease control Recruiting nowThis study tests a weekly combination of chemotherapy (carboplatin and paclitaxel) plus immunotherapy (pembrolizumab) in 32 people with metastatic head and neck cancer who cannot take the standard drug 5-fluorouracil. The goal is to see if this regimen shrinks tumors better than …
Matched conditions: METASTATIC SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated May 19, 2026 12:00 UTC